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Familial adenomatous polyposis (FAP) is an autosomal dominant inherited syndrome, caused by germline
mutations in the adenomatous polyposis coli (APC) suppressor gene. Patients with colorectal polyps are
more likely to develop a malignant condition with poor prognosis. Typical FAP is characterized by
hundreds to thousands of colorectal adenomatous polyps and by several extra-colonic manifestations; an
attenuated form of polyposis (AFAP), presenting less than 100 adenomas and later onset, has been
reported.
In this study we have examined ﬁve Sicilian families affected by FAP syndrome, in order to provide
predictive genetic testing for the affected families, as well as to contribute to mutation catalog
enrichment.
We have detected different APC mutations in these ﬁve pedigrees, conﬁrming the remarkable het-
erogeneity of the mutational spectrum in FAP.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Familial adenomatous polyposis (FAP) (MIM 175100) is an
autosomal-dominant precancerous condition characterized by the
appearance of hundreds to thousands of adenomatous polyps
throughout the entire colorectum that may result in colorectal
cancers [1].
Furthermore, FAP can be characterized by the presence of polyps
and adenomas in the stomach and duodenum, desmoid tumors
(inﬁltrative ﬁbromatosis), congenital hypertrophy of the retinal
pigment epithelium, osteomas and sebaceous cysts (epidermoid
cysts), epatoblastoma, fundic gland polyposis, pancreatic and, Organ Transplantation and
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by Elsevier Ltd. All rights reservedthyroid cancers, dental abnormalities and malignant of the central
nervous system [2e5].
APC is a tumor suppressor gene located on the long arm of the
chromosome 5 in band q21 (5q21). The coding region is divided
into 15 exons (with a particularly large 15th exon that cover about
76% of the coding region with its 6774 bp) and with its 8529 bp
open reading frame encodes a large protein (309 kilo-Daltons)
composed of 2843 amino acids [6,7]
The APC protein has multiple domains that mediate oligomeri-
zation as well as binding to a variety of intercellular proteins, which
have an important role in cell adhesion, signal transduction and
transcriptional activation.
Loss of normal APC function is known to be an early event in
both familiar and sporadic colon cancer pathogenesis occurring at
the preadenoma stage [8]
Mutations of the APC gene have been implicated in familial
adenomatous polyposis as well as sporadic colorectal tumors, as
they are involved in the early stage of colorectal tumorigenesis..
Fig. 1. Family n.1 tree.
Fig. 2. Family n.2 tree.
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truncated protein due to a premature stop codon or frame shifts.
About 60% of the APC mutations in sporadic colorectal tumors
are clustered in the central domain of APC (amino acids
1284e1580), also called mutation cluster region (MCR) [9]. In
addition to the tumor suppressor function of colorectal tumors, APC
protein has been demonstrated to possess many other functions,
including regulation of cell proliferation, differentiation and
migration [10].
Considering the high grade of penetrance in FAP mutations
carriers and the high relevance of genetic diagnostic test for early
detection and prevention of cancer, we decided to performed a
screening of the APC gene in patients with FAP syndrome.
In this paper we report the identiﬁcation of germline APC mu-
tations in ﬁve unrelated FAP Sicilian families.2. Materials and methods
2.1. Patients
All patients with Sicilian origin were recruited through cancer
centers and gastroenterology services in Sicilian medicalFig. 3. Family n.3 tree.institutions. Probands have been initially identiﬁed by the presence
of more than 100 colorectal polyps on endoscopic examination
and/or by a family history of FAP.
In our patients or their relatives no other lesions associated with
the polyposis were found, except for a member of FAM4 (III:1), who
presented desmoid tumors.
Among members of FAP families, several adenocarcinomas have
been diagnosed before 40 years of age. Genetic analysis of each
family was included at least one symptomatic case.
Informed consent was obtained from all participants before
testing. Genealogical trees of all families were prepared during
genetic counseling (Figs. 1e5).
FAMILY 1: family history was positive for FAP and colic tumors
(I:2, II:1, II:3, II:5, II:7). The proband III:8, underwent endoscopic
examination at the age of 10 for suspicion of FAP, but no polyps
were found. Five years later a new endoscopic examination
revealed several colic polyps. Since then the patient has been
subjected topolypectomy in different endoscopic sessions.
FAMILY 2: the proband (III:1) at the age of 37 years was diag-
nosed with FAP syndrome and colectomized. Other family
members, I:1, II:1, II:2, II:4, III:4 and III:6 were subjected to total
colectomy for polyposis and other colic tumors.
FAMILY 3: the proband (II:1) was colectomized for FAP at the
age of 45. His father (I:1) died for colon cancer and his sister
(II:3) was colectomized for FAP at the age of 40.
FAMILY 4: the proband (III:3)was colectomized for diffuse pol-
yposis at the age of 20. Her mother (II:1) died for colon cancer at
the age of 40 and her brother (III:1), who presented desmoid
tumors, was colectomized for Gardner's Syndrome at the age of
18; uncles (II:3, II:4, II:5, II:7) were also affected by FAP
syndrome.
FAMILY 5: the proband (III:1) was colectomized for colon cancer,
associated with diffuse polyposis, at the age of 38. Subjects II:1,
II:3 and III:6 were referred to as being affected of polyposis andFig. 4. Family n.4 tree.
Table 2
Family members showing the speciﬁc gene alteration after genetic counseling.
Family ID Proband Positive relatives
FAM1 III:8 III:1, III:3, III:7
FAM2 III:1 IV:1
FAM3 II:1 II:3, III:1, III:3, III:6
FAM4 III:3 e
FAM5 III:1 IV:2, IV:9, V:1
Fig. 5. Family n.5 tree.
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individuals asked to attend colonoscopy following mutation
identiﬁcation.3. Methods
3.1. DNA extraction and PCR ampliﬁcation
After informed consent, blood samples were obtained from
affected individuals. Genomic DNA was puriﬁed by the phenol-
chloroform method and stored at 20 C.
Mutation analysis of APC gene was performed using PCR
ampliﬁcation covering coding sequences and introneexon bound-
aries of exons 1 to 14 and segments of exon 15 was performed using
the primers reported elsewhere [6].
Ampliﬁcation products were run by 2% agarose gel electropho-
resis stained with SYBR Safe DNA gel stain.3.2. Direct sequencing of PCR-ampliﬁed fragments
Direct sequencing of ampliﬁed products was performed to
determine sequence changes. Each ampliﬁed product was puriﬁed
by a Montage PCR Centrifugal Filter (Millipore) to remove unin-
corporated precursors. The puriﬁed fragments were then
sequenced by using the ﬂuorescent BigDye Terminator Chemistry
(Applied Biosystems, Foster City, CA, USA) according to the manu-
facturer's protocol and analyzed by using a DNA automated ABI
PRISM 310 Genetic Analyzer (Applied Biosystems). The results of
sequencing analysis were compared with wild-type samples and
the normal sequencing of the APC gene (OMIM 175100; Gen Bank:
4557318). Mutations were conﬁrmed by two independent PCR re-
actions and by sequencing both strands.le 1
mutations found in proband's families.
mily ID Codon Exon Mutation Mutation type Consequence
M 1 1062 15 c.3186-3187delAA Frameshift Chain ter
M 2 1981 15 c.5942delA Frameshift Chain ter
M 3 1104 15 c.3311C>A (S1104X) Nonsense Chain ter
M 4 1309 15 c.3927-3931delAAAGA Frameshift Chain ter
M 5 624 14 c.1875-1878delGACA Frameshift Chain ter4. Results
In Table 1 are reported the different APC mutations found in
proband's families, four deletions and a single substitution. Muta-
tions are named according to the nomenclature proposed by the
Human Genome Variation Society (http://www.hgvs.org/
mutnomen/).
In the ﬁve informative families the germinal mutation was
conﬁrmed in several family members at risk. These individuals had
not previously been analyzed and were all asymptomatic.
In Table 2 are described all family members showing the speciﬁc
gene alteration after genetic counseling.
5. Discussion
Truncating germline mutation in the APC gene are responsible
for 70e90% of FAP cases [11].
Only one study clearly reports a characterized APC mutation
from a Sicilian family with FAP [12].
All the mutations of the APC gene, found in our probands, cause
the introduction of premature stop codons and consequent for-
mation of a truncated protein.
The ﬁrst deletion, found in the FAM1, results in the loss of two
bases (eAA) in codon 1062. Although rarely reported [13] this
deletion overlaps with a mutational hot-spot of the FAP syndrome,
codons 1062 and 1063, and involves the binding site for beta-
catenin [14]. Interestingly, we learned that the individual, exam-
ined in Gismondi's study and carrying the same deletion, was of
Sicilian origin. This observation suggests that this mutation may be
recurrent in the Sicilian population even if larger number of in-
dividuals affected by FAP are needed to evaluate the prevalence of
such mutation.
The second deletion, found in the FAM2, results in the loss of one
single base (eA), in codon 1981, as previously described by Scott
et al. [15].
In the FAM4, we found another deletion, which consists in the
loss of 5 bp (eAAAGA) in codon 1309, as previously described by
Miyoshi et al. [16]. This deletion falls within a region where the
mutation has been shown to have a strong correlation with one of
the features of the Gardner's syndrome such as the presence of
desmoids, observed in the proband's brother. A fourth deletionwas
found in the FAM5, and results in the loss of 4 bp (eGACA) in codon
624 as previously described by Nagase et al. [17].
FAM3was characterized by themutation c.3311C>A, that results
in a truncated APC protein causing the FAP phenotype [18]. It
consists in a substitution (TCA > TAA) in codon 1104 causing a stop-
codon, in position of serine.
This mutation falls in the region of exon 15, comprised between
codons 876 and 1344, that correlates with extra-colic adenomas
manifestation and the hypertrophy of the retinal pigment epithe-
lium (CHRPE) phenotype. It is interesting to notice that the proband
(II:1) and her sister (II:3) manifested retinal anomalies and
epidermoid cysts on the back.
The diagnosis of FAP, in probands and in the majority of their
relatives, was made after ﬁnding colonic polyps in colonoscopy. For
A. Russo et al. / International Journal of Surgery 12 (2014) S125eS129S128some of them, it was not possible to perform the colonoscopy
because of the young age or patient refusal to have endoscopic
interventions [19e21].
In conclusion, most of APC gene alterations here reported are
small deletions previously described in other FAP individuals.
Interestingly, the present study allow us to identify a newmutation
in a Sicilian family with FAP history.
We believe that enlargement of the APC mutation spectrum
with these types of studies will contribute to early detection of
patients with FAP from different populations and to the prevention
of colorectal cancer formation [22e29].
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